Clinical Significance of POU5F1P1 rs10505477 polymorphism in Chinese gastric cancer patients receving cisplatin-based chemotherapy after surgical resection

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12764-12777

  Shen, Lili ^a   Du, Mulong ^b,c   Wang, Chun ^a   Gu, Dongying ^a   Wang, Meilin ^b,c   Zhang, Qi ^a   Zhao, Tingting ^a   Zhang, Xunlei ^d   Tan, Yongfei ^e   Huo, Xinying ^a   Gong, Weida ^f   Xu, Zhi ^a   Chen, Jinfei ^a   Zhang, Zhengdong ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Nanjing Medical University   (China)

^d Tumor Hospital of Nantong City   (China)

^e YIXING PEOPLE S HOSPITAL   (China)

^f Yixing People's Hospital   (China)

Author keywords

Cisplatin based chemotherapy; Gastric cancer; POU5F1P1 rs10505477 polymorphism; Single nucleotide polymorphism (SNP)

Indexed keywords

CISPLATIN; GENOMIC DNA; OXALIPLATIN; HOMEODOMAIN PROTEIN; POU5F1P1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; DNA POLYMORPHISM; FEMALE; GASTRECTOMY; GENE; GENETIC ANALYZER; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAZARD RATIO; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POU5F1P1 GENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR INVASION; TUMOR VOLUME; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; STOMACH NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CISPLATIN; FEMALE; GASTRECTOMY; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84904488811     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712764     Document Type: Article

References (47)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2014, 64, 9-29.
2. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
3. Santoro, R.; Carboni, F.; Lepiane, P.; Ettorre, G. M.; Santoro, E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br. J. Surg. 2007, 94, 737-742.
4. Takaishi, S.; Okumura, T.; Wang, T. C. Gastric cancer stem cells. J. Clin. Oncol. 2008, 26, 2876-2882.
5. Takaishi, S.; Okumura, T.; Tu, S.; Wang, S. S.; Shibata, W.; Vigneshwaran, R.; Gordon, S. A.; Shimada, Y.; Wang, T. C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27, 1006-1020.
6. Han, M. E.; Jeon, T. Y.; Hwang, S. H.; Lee, Y. S.; Kim, H. J.; Shim, H. E.; Yoon, S.; Baek, S. Y.; Kin, B. S.; Kang, C. D.; et al. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell. Mol. Life Sci. 2011, 68, 3589-3605.
7. Tatematsu, M.; Tsukamoto, T.; Inada, K. Stem cells and gastric cancer: Role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci. 2003, 94, 135-141.
8. Zhang, C.; Li, C.; He, F.; Cai, Y.; Yang, H. Identification of CD44+CD24+ gastric cancer stem cells. J. Cancer Res. Clin. Oncol. 2011, 137, 1679-1686.
9. Alison, M. R.; Poulsom, R.; Forbes, S.; Wright, N. A. An introduction to stem cells. J. Pathol. 2002, 197, 419-423.
10. Pan, G. J.; Chang, Z. Y.; Scholer, H. R.; Pei, D. Stem cell pluripotency and transcription factor OCT4. Cell Res. 2002, 12, 321-329.
11. Boyer, L. A.; Lee, T. I.; Cole, M. F.; Johnstone, S. E.; Levine, S. S.; Boyer, LA, Zucker, J. P.; Guenther, M. G.; Kumar, R. M.; Murray, H. L.; et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122, 947-956.
12. Cheng, C. J.; Wu, Y. C.; Shu, J. A.; Ling, T. Y.; Kuo, H. C.; Wu, J. Y.; Chang, E. E.; Chang, S. C.; Huang, Y. H. Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. J. Biomed. Sci. 2007, 14, 797-807.
13. Matsuoka, J.; Yashiro, M.; Sakurai, K.; Kubo, N.; Tanaka, H.; Muguruma, K.; Sawada, T.; Ohira, M.; Hirakawa, K. Role of the stemness factors Sox2, OCT3/4 and nanog in gastric carcinoma. J. Surg. Res. 2012, 174, 130-135.
14. Suo, G.; Han, J.; Wang, X.; Zhang, J.; Zhao, Y.; Zhao, Y.; Dai, J. OCT4 pseudogenes are transcribed in cancers. Biochem. Biophys. Res. Commun. 2005, 337, 1047-1051.
15. Panagopoulos, I.; Moller, E.; Collin, A.; Mertens, F. The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1. Oncol. Rep. 2008, 20, 1029-1033.
16. Pal, P.; Xi, H.; Guha, S.; Sun, G.; Helfand, B. T.; Meeks, J. J.; Suarez, B. K.; Catalona, W. J.; Deka, R. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. Prostate 2009, 69, 1548-1556.
17. Wei, W.; Jiang, M.; Luo, L.; Li, Z.; Wang, P.; Dong, W. Q. Colorectal cancer susceptibility variants alter risk of breast cancer in a Chinese Han population. Genet. Mol. Res. 2013, 12, 6268-6274.
18. Gruber, S. B.; Moreno, V.; Rozek, L. S.; Rennerts, H. S.; Lejbkowicz, F.; Bonner, J. D.; Greenson, J. K.; Giordano, T. J.; Fearson, E. R.; Rennert, G. Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol. Ther. 2007, 6, 1143-1147.
19. Poynter, J. N.; Figueiredo, J. C.; Conti, D. V.; Kennedy, K.; Gallinger, S.; Siegmund, K. D.; Casey, G.; Thibodeau, S. N.; Jenkins, M. A.; Hopper, J. L.; et al. Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: Results from the colon cancer family registry. Cancer Res. 2007, 67, 11128-11132.
20. Schafmayer, C.; Buch, S.; Volzke, H.; von Schonfels, W.; Egberts, J. H.; Schniewind, B.; Brosch, M.; Ruether, A.; Franke, A.; Mathiak, M.; et al. Investigation of the colorectal cancer susceptibility region on chromosome 8q24. 21 in a large German case-control sample. Int. J. Cancer 2009, 124, 75-80.
21. Dai, J.; Gu, J.; Huang, M.; Eng, C.; Kopetz, E. S.; Ellis, L. M.; Hawk, E.; Wu, X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 2012, 33, 1327-1331.
22. Hutter, C. M.; Slattery, M. L.; Duggan, D. J.; Muehling, J.; Curtin, K.; Beresford, S. A.; Rajkovic, A.; Sarto, G. E.; Marshall, J. R.; et al. Characterization of the association between 8q24 and colon cancer: Gene-environment exploration and meta-analysis. BMC Cancer 2010, 10, 670.
23. White, K. L.; Sellers, T. A.; Fridley, B. L.; Vierkant, R. A.; Phelan, C. M.; Tsai, Y. Y.; Kalli, K. R.; Berchuck, A.; Iversen, E. S.; Hartmann, L. C.; et al. Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin. Res. Hum. Genet. 2010, 13, 43-56.
24. Lochhead, P.; Ng, M. T. H.; Hold, G. L.; Rabkin, C. S.; Vaughan, T. L.; Gammon, M. D.; Risch, H. A.; Lissowska, J.; Mukhopadhya, I.; Chow, W. H.; et al. Possible association between a genetic polymorphism at 8q24 and risk of upper gastrointestinal cancer. Eur. J. Cancer. Prev. 2011, 20, 54-57.
25. Zhang, Y.; Wang, M.; Gu, D.; Wu, D.; Zhang, X.; Gong, W.; Tan, Y.; Zhou, J.; Wu, X.; Tang, C; et al. Association of XRCC1 gene polymorphisms with the survival and clinicopathological characteristics of gastric cancer. DNA Cell Biol. 2013, 32, 111-118.
26. Zhang, X.; Zhu, H.; Wu, X.; Wang, M.; Gu, D.; Gu, D.; Gong, W.; Xu, Z.; Tan, Y.; Gong, Y.; et al. A genetic polymorphism in TOX3 is associated with survival of gastric cancer in a Chinese population. PLoS One 2013, 8, e72186.
27. Zhang, Y.; Zhu, H.; Zhang, X.; Gu, D.; Zhou, X.; Wang, M.; Cao, C.; Zhang, X.; Wu, X.; Gong, W.; et al. Clinical significance of MYT1L gene polymorphisms in Chinese patients with gastric cancer. PLoS One 2013, 8, e71979.
28. Spradling, A.; Drummond-Barbosa, D.; Kai, T. Stem cells find their niche. Nature 2001, 414, 98-104.
29. Ezeh, U. I.; Turek, P. J.; Reijo, R. A.; Clark, A. T. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 104, 2255-2265.
30. Wen, K.; Fu, Z.; Wu, X.; Feng, J.; Chen, W.; Qian, J. OCT-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: Effects associated with STAT3/Survivin. Cancer Lett. 2013, 333, 56-65.
31. Davidson, K. C.; Adams, A. M.; Goodson, J. M.; McDonald, C. E.; Potter, J. C.; Berndt, J. D.; Biechele, T. L.; Taylor, R. J.; Moon, R. T. Wnt/β-catenin signaling promotes differentiation not self-renewal of human embryonic stem cells and is repressed by OCT4. Proc. Natl. Acad. Sci. USA 2012, 109, 4485-4490.
32. Wang, X. Q.; Ongkeko, W. M.; Chen, L.; Yang, Z. F.; Lu, P.; Chen, K. K.; Lopez, J. P.; Poon, R. T.; Fan, S. T. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 2010, 52, 528-539.
33. Kastler, S.; Honold, L.; Luedeke, M.; Kuefer, R.; Moller, P.; Hoegel, J.; Vogel, W.; Maier, C.; Assum, G. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. Prostate 2010, 7, 666-674.
34. Cunningham, D.; Rao, S.; Starling, N.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A. R. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J. Clin. Oncol. 2006, 24, 18S.
35. Kim, Y. S.; Sym, S. J.; Park, S. H.; Park, I.; Hong, J.; Ahn, H. K.; Park, J.; Cho, E. K.; Lee, W. K.; Chung, M.; et al. A randomized phase II study of weekly docetaxel/cisplatin vs. weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Cancer Chemother. Pharmacol. 2014, 73, 163-169.
36. Al-Batran, S. E.; Hartmann, J. T.; Probst, S.; Schmalenberg, H.; Hollerbach, S.; Hofheinz, R.; Rethwisch, V.; Seipelt, G.; Homann, N.; Wilhelm, G.; et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the arbeitsgemeinschaft internistische onkologie. J. Clin. Oncol. 2008, 26, 1435-1442.
37. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
38. Stewart, D. J. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007, 63, 12-31.
39. Chu, W.; Pak, B. J.; Bani, M. R.; Kapoor, M.; Lu, S. J.; Tamir, A.; Kerbel, R. S.; Ben-David, Y. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diammine dichloroplatinum(II): Therapeutic implications. Oncogene 2000, 19, 395-402.
40. Mizutani, Y.; Bonavida, B. Overcoming cis-diamminedichloroplatinum(II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum(II) and tumor necrosis factor-α. Cancer 1993, 72, 809-818.
41. Liu, L. Z.; Zhou, X. D.; Qian, G.; Shi, X.; Fang, J.; Jiang, B. H. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007, 67, 6325-6332.
42. Meijer, C.; Mulder, N. H.; Timmer-Bosscha, H.; Sluiter, W. J.; Meersma, G. J.; de Vries, E. G. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992, 52, 6885-6889.
43. Zhang, L. L.; Zhang, J.; Shen, L.; Xu, X. M.; Yu, H. G. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo. Mol. Med. Rep. 2013, 7, 1387-1390.
44. Huang, S.; Chen, M.; Shen, Y.; Shen, W.; Guo, H.; Gao, Q.; Zuo, X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett. 2012, 315, 198-205.
45. Xu, N.; Shen, C.; Luo, Y.; Xia, L.; Xue, F.; Xia, Q.; Zhang, J. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem. Biophys. Res. Commun. 2012, 425, 468-472.
46. Gosepath, E. M.; Eckstein, N.; Hamacher, A.; Servan, K.; von Jonquieres, G.; Lage, H.; Györffy, B.; Royer, H. D.; Kassack, M. U. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int. J. Cancer 2008, 123, 2013-2019.
47. Biroccio, A.; Benassi, B.; Fiorentino, F.; Zupi, G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004, 6, 195-206.